ID-alG™ (Ascophyllum Brown Seaweed for Weight Management)

Ascophyllum nodosum
Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

ID-alG™ is a STANDARDIZED BROWN SEAWEED EXTRACT from Ascophyllum nodosum (Atlantic brown algae) developed by Nexira (France) — designed to limit fat and sugar storage via marine polyphenol enzyme inhibition. Distinguished by guaranteed >50% inhibition activity on lipase and α-amylase (in tubo), clinical evidence for weight loss with body composition improvements (fat mass reduction, decreased HbA1c), and target demographic of women 45+. Manually harvested from rocky North Atlantic coasts, processed in France.

Studied Dose 400 mg/day (research-validated dose)
Active Compound Marine polyphenols (phlorotannins) standardized for enzyme inhibition activity

Benefits

Lipase and α-Amylase Inhibition (Fat and Carb Blocking)

ID-alG™ inhibits two main digestive enzymes — pancreatic lipase (fat digestion) and α-amylase (starch digestion). Reduces absorption of dietary fats and carbohydrates. >50% enzyme inhibition guaranteed. Foundational mechanism.

Weight Loss with Body Composition Improvement

Nexira clinical study showed significant weight loss correlated with fat mass reduction; decreased abdominal and visceral fat; significant reduction in carb assimilation and HbA1c (glycated hemoglobin). Established in target demographic.

HbA1c Reduction

Reduction in glycated hemoglobin reflects improved long-term glucose control. Mechanism: reduced carbohydrate absorption from α-amylase inhibition + reduced glucose excursions over time. Modest but meaningful for metabolic health.

Body Shape Improvement

Reduction of abdominal and visceral fat — visible body shape improvement beyond just weight loss. Particularly relevant for older women's body composition concerns.

User Satisfaction Validation

Nexira survey: 76% convinced of weight management effect; 72% would continue using ID-alG™. High user satisfaction reflects perceived efficacy and tolerability.

Mechanism of action

1

Phlorotannin Enzyme Inhibition

Phlorotannins (marine polyphenols specific to brown algae; structurally similar to terrestrial tannins but distinct chemistry) inhibit pancreatic lipase and α-amylase via enzyme-substrate competitive inhibition. Reduces digestion/absorption of fats and starches.

2

Reduced Caloric Intake from Macronutrient Blocking

Lipase inhibition reduces fat absorption; α-amylase inhibition reduces starch absorption. Net caloric reduction supports weight management. Same mechanism category as orlistat (pharmaceutical lipase inhibitor) but weaker effect with better tolerability.

3

Soluble Fiber Component

Ascophyllum nodosum also provides soluble fiber (alginates, fucoidan) — additional satiety and microbiome effects.

4

Iodine Content Consideration

Brown seaweeds naturally contain iodine; concentrated extracts have variable iodine content — Nexira processes for safe iodine levels in supplemental form. Verify product specifications.

Clinical trials

1
ID-alG™ for Weight Management — Nexira Clinical Study
PubMed

RCT of ID-alG™ on weight, body composition, and metabolic markers.

Adults with weight management concerns (women 45+ target).

Significant weight loss correlated with fat mass; decreased fat assimilation, body fat mass, abdominal/visceral fat; reduced carb assimilation and HbA1c; body shape improvement; no signs of discomfort.

2
Ascophyllum nodosum Phlorotannin Research
PubMed

Multiple studies of brown algae phlorotannins on enzyme inhibition and metabolic effects.

In vitro and clinical.

Established phlorotannin-mediated lipase and α-amylase inhibition; modest clinical metabolic effects. Foundation for evidence-based marine algae weight management applications.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Mild GI distress (loose stools possible from fat malabsorption — mild form of orlistat-type effect).
Allergic reactions to seaweed/iodine rare.
Iodine effects in those with thyroid conditions (excess iodine concerning for those with autoimmune thyroid disease).
Possible contamination with heavy metals (arsenic from sea) — reputable processing addresses; verify quality.
Algal taste / smell rare with capsule format.

Important Drug interactions

DIABETES MEDICATIONS — additive hypoglycemic effects from carb absorption reduction; monitor.
ANTICOAGULANTS — fucoidan in brown algae has anticoagulant activity; theoretical bleeding risk.
THYROID MEDICATIONS — iodine content may affect thyroid function; consult.
Fat-soluble vitamins (A, D, E, K) — theoretical reduced absorption from fat blocking; consider supplement timing.
Medications absorbed with fat — theoretical reduced absorption.
PREGNANCY — limited specific safety data; iodine content concerns in pregnancy (excess iodine can cause fetal thyroid issues); AVOID.
Lactation — AVOID.

Frequently asked questions about ID-alG™ (Ascophyllum Brown Seaweed for Weight Management)

What is the recommended dosage of ID-alG™ (Ascophyllum Brown Seaweed for Weight Management)?

The clinically studied dose for ID-alG™ (Ascophyllum Brown Seaweed for Weight Management) is 400 mg/day (research-validated dose). Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is ID-alG™ (Ascophyllum Brown Seaweed for Weight Management) used for?

ID-alG™ (Ascophyllum Brown Seaweed for Weight Management) is studied for lipase and α-amylase inhibition (fat and carb blocking), weight loss with body composition improvement, hba1c reduction. ID-alG™ inhibits two main digestive enzymes — pancreatic lipase (fat digestion) and α-amylase (starch digestion). Reduces absorption of dietary fats and carbohydrates. >50% enzyme inhibition guaranteed. Foundational mechanism.

Are there side effects from taking ID-alG™ (Ascophyllum Brown Seaweed for Weight Management)?

Reported potential side effects may include: Generally well-tolerated. Mild GI distress (loose stools possible from fat malabsorption — mild form of orlistat-type effect). Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does ID-alG™ (Ascophyllum Brown Seaweed for Weight Management) interact with medications?

Known drug interactions may include: DIABETES MEDICATIONS — additive hypoglycemic effects from carb absorption reduction; monitor. ANTICOAGULANTS — fucoidan in brown algae has anticoagulant activity; theoretical bleeding risk. Consult a pharmacist or healthcare provider if you take prescription medications.

Is ID-alG™ (Ascophyllum Brown Seaweed for Weight Management) good for weight management?

Yes, ID-alG™ (Ascophyllum Brown Seaweed for Weight Management) is researched for Weight Management support. Nexira clinical study showed significant weight loss correlated with fat mass reduction; decreased abdominal and visceral fat; significant reduction in carb assimilation and HbA1c (glycated hemoglobin). Established in target demographic.